Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial
Eve T. Rodler(UC Davis Comprehensive Cancer Center), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center), Thu-Tam Huynh(Kaiser Permanente Anaheim Medical Center), Harsh B. Pathak(University of Kansas Medical Center), Lajos Pusztai(Yale University), Julie R. Gralow(American Society of Clinical Oncology), Andrew K. Godwin(The University of Melbourne), Kirsten M. Timms(Myriad (Germany)), Ursa Brown‐Glaberman(University of New Mexico), Priyanka Sharma(Chandigarh University), Lori J. Goldstein(Shaanxi Research Association for Women and Family), Christopher S Szyarto(University of Michigan–Flint), Marc R. Radke(University of Washington), Daniel F. Hayes(University of Michigan–Ann Arbor), William E. Barlow(Cancer Research And Biostatistics), Elizabeth M. Swisher(University of Washington), Shannon L. Puhalla(NSABP Foundation), Debu Tripathy(The University of Texas MD Anderson Cancer Center), Danika L. Lew, Jieling Miao, Carey K. Anders(Duke University)
Cited by 103
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Current and future burden of breast cancer: Global statistics for 2020 and 2040
|The Breast|2022|3.3k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k